Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization

NCT00027248 is registered in ClinicalTrials.gov with BioWest Therapeutics Inc as lead sponsor.

NCT NCT00027248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00027248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization
Lead sponsor
BioWest Therapeutics Inc
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
July 31, 2003
Enrollment
1,400
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia, fungemia, sepsis